AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01567202 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
Study NCT01567202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
Study NCT01567202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank placebo
Description: Saline that has the same appearance with DC vaccine.
Study NCT02084680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health workers
Description: community health workers offering individual prenatal education to pregnant women
Study NCT03032614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
Study NCT03032614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin Mesylate is a synthetic halichondrin analog.
Study NCT04062331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
Study NCT03137472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
Study NCT03137472 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
Study NCT03358290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-051
Description: Active drug tablets containing JTE-051
Study NCT03358290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical in appearance to the active drug tablets
Study NCT00416078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caregiver website support
Description: caregiver access to website support for 6 months embedded in one year of customary care
Study NCT00416078 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: caregiver brief supportive phone calls
Description: caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
Study NCT03473808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: task-practice therapy
Description: Standardized hand therapy program
Study NCT03473808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Peripheral vibration applied to the wrist skin at an imperceptible level
Study NCT02520401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic - BioGaia
Description: Use of a probiotic tablet
Study NCT02520401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of a placebo tablet
Study NCT03807063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rivogenlecleucel
Description: Given IV
Study NCT03807063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Given IV
Study NCT01272414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 2-12 units in weekly 2u doses to effect
Study NCT01272414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Injection of 0.4cc 0.9% normal saline
Study NCT03032614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
Study NCT03835884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 Implant 10.6 Dose
Description: AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
Study NCT03835884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 Implant 21.2 Dose
Description: AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
Study NCT04325425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3
Study NCT01584167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Study NCT03835884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 42.4 Dose
Description: AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
Study NCT03835884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 63.6 Dose
Description: AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
Study NCT01175642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-based, therapist-lead cognitive remediation
Study NCT01175642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Computer-based, therapist-lead cognitive remediation
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil
Study NCT01175642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAST
Description: Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
Study NCT01669421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin (human)
Description: Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Study NCT03589391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOR measurement via device
Description: The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
Study NCT04202510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma and Cataract Surgery
Description: Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
Study NCT04197063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweetened beverage portion size limit
Study NCT04183855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generation UCAN supplementation
Description: carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
Study NCT04183855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mirexus PhytoSpherix supplementation
Description: carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
Study NCT04183855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: satiety ratings
Description: questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
Study NCT01994772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted controlled temperature between 32.5 and 33.5°C
Description: Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
Study NCT01994772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted controlled temperature between 36.5 and 37.5°C
Description: Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
Study NCT01994772 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Targeted controlled temperature between 36.5 and 37.5°C
Description: Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
Study NCT01605227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally once-daily
Study NCT01605227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Study NCT00874406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tac + folfox4
Description: tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
Study NCT00874406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folfox4
Description: folfox4 will be done within 28 days after liver resection
Study NCT01836796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri
Description: 100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
Study NCT01836796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri DSM17938
Description: Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
Study NCT01836796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Reuteri DSM17938
Description: Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
Study NCT02362230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib 125 mg BID
Study NCT05499338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching program
Description: The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
Study NCT00183378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Program
Description: The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
Study NCT00183378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Exposure Program
Description: The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
Study NCT00183378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Education, Walking and Light Exposure Program
Description: The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
Study NCT00183378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Medical Care with Education
Description: The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
Study NCT02501720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post burn flexion contractures release under tourniquet control
Description: post burn flexion contractures will be released under tourniquet control
Study NCT02501720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post burn flexion contractures release using tumescent solution
Description: post burn flexion contractures will be released using tumescent solution
Study NCT02501720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contracture release and application of FTSG
Description: Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
Study NCT02501720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contracture release and application of FTSG
Description: Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
Study NCT02418208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Performint EEG tests and BNA analysis
Study NCT02510365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Functional collagen scaffold
Description: Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
Study NCT00743028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Donepezil
Study NCT01584167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMCOOLS Flex.Pads
Description: Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
Study NCT02718339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive counseling
Study NCT04530370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recovered covid 19 patients plasma
Description: we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
Study NCT04530370 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recovered covid 19 patients plasma
Description: we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel
Study NCT02399319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symphyseal Plate
Description: A plate that spans across the symphysis to maintain reduction and stability.
Study NCT01590797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg once daily for 24 weeks
Study NCT01590797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily for 24 weeks
Study NCT01590797 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
Study NCT01590797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
Study NCT01590797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
Study NCT01590797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
Study NCT04626648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pause with a sugar containing drink
Description: Three-minute long intraoperative pause, including a sugar-containing drink
Study NCT01692366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:Capsule~Route of administration: oral
Study NCT03352206 — intervention group
Intervention type: DRUG
Intervention: 2 drug dose - DA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
Study NCT03352206 — intervention group
Intervention type: DRUG
Intervention: 3 drug dose - IDA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Study NCT00989014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47
Description: 0.5% Topical Gel
Study NCT00989014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47
Description: 0.18% Topical Gel
Study NCT00989014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47
Description: 0.07% Topical Gel
Study NCT00989014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD07805/47 placebo
Description: Vehicle Topical Gel
Study NCT02872467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon treatment
Description: 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
Study NCT02872467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
Study NCT01132131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delegation form
Description: The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
Study NCT05548829 — intervention group
Intervention type: BIOLOGICAL
Intervention: Disease severity
Description: Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
Study NCT01013701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: nasal steroid spray
Study NCT01013701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nasal steroid vehicle without drug
Study NCT04350788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survivorship Care Plan
Description: Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
Study NCT04350788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Survivorship Care Plan
Description: In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
Study NCT04617444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.